News FDA approves leucovorin – but not for autism The FDA stops short of approving leucovorin for autism, but will its clearance for ultra-rare condition CFD-FOLR1 lead to more off-label prescribing?
News Alfasigma licenses liver drug from GSK in $690m deal With an FDA verdict looming, GSK has signed an eleventh-hour deal to give Alfasigma rights to its primary biliary cholangitis therapy linerixibat.
News GSK grows pipeline with 35Pharma takeover, Frontier deal GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.
News EU approval for new asthma drug Exdensur lifts GSK EU approval takes GSK a step closer to fulfilling its blockbuster sales hopes for new long-acting respiratory drug Exdensur.
News GSK delivers in new CEO Miels' first financial update Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits.
News GSK departs Wave's AATD programme Wave Life Sciences has lost GSK as the partner for its alpha-1 antitrypsin deficiency drug, but other partnered RNA-editing programmes remain active.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.